Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: The impact of cardiovascular risk factor load

Menopause

Volumn 23, Issue 1, 2016, Pages 55-59

  Feldbrin, Zeev ^a,b   Luckish, Alla ^a   Shargorodsky, Marina ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bisphosphonates; Cardiovascular risk factors; Ferritin; Postmenopausal osteoporosis

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; PARATHYROID HORMONE; RISEDRONIC ACID; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; BONE DENSITY CONSERVATION AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN; LIPID;

ARTERY COMPLIANCE; ARTICLE; AUGMENTATION INDEX; BLOOD SAMPLING; BONE DENSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULSE WAVE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR;

AGED; BONE DENSITY CONSERVATION AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LINEAR MODELS; LIPIDS; LIPOPROTEINS, HDL; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POSTMENOPAUSE; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; RESEARCH DESIGN; RISEDRONATE SODIUM; RISK FACTORS; TIME FACTORS;

EID: 84952673813     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000480     Document Type: Article

References (16)

1. Halle M, König D, Berg A, Keul J, Baumstark MW. Relationship of serum ferritin concentrations with metabolic cardiovascular risk factors in men without evidence for coronary artery disease. Atherosclerosis 1997;128:235-240.
2. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003;325:332-339.
3. Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol Lett 2009;191:211-215.
4. Yang Q, Jian J, Abramson SB, Huang X. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 2011;26:1188-1196.
5. Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 2010;116:2582-2589.
6. Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1b and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009;15:259-266.
7. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005;16:1809-1814.
8. Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: A frequent and still unresolved problem. J Bone Miner Res 2009;24:543-557.
9. Kim BJ, Ahn SH, Bae SJ, et al. Iron overload accelerates bone loss in healthy postmenopausal women and middle-Aged men: A 3-year retrospective longitudinal study. J Bone Miner Res 2012;27:2279-2290.
10. Asmar RG, London GM, ORourke MF, Safar ME. REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension 2001;38:922-926.
11. ORourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical application of arterial stiffness; definitions and reference values. Am J Hypertens 2002;15:426-444.
12. Koorts AM, Viljoen M. Ferritin and ferritin isoforms II: protection against uncontrolled cellular proliferation, oxidative damage and inflammatory processes. Arch Physiol Biochem 2007;113:55-64.
13. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12, 033 men. Arterioscler Thromb Vasc Biol 2012;32:2525-2530.
14. Lee KR, Sweeney G, Kim WY, Kim KK. Serum ferritin is linked with aortic stiffness in apparently healthy Korean women. Crit Pathw Cardiol 2010;9:160-163.
15. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011;21:568-575.
16. Kim BJ, Lee SH, Koh JM, Kim GS. The association between higher serum ferritin level and lower bone mineral density is prominent in women-45 years of age (KNHANES 2008-2010). Osteoporos Int 2013;24:2627-2637.